Telix Pharmaceuticals Appoints David Gill to Board; Announces Company Secretary Transition

On April 2, 2026, Telix Pharmaceuticals Limited announced the appointment of David Gill as a Non-Executive Director, effective May 11, 2026. Mr. Gill is a life sciences veteran with over 35 years of experience, having held senior leadership and CFO roles at companies including INC Research and CTI Molecular Imaging. The company expects Mr. Gill to eventually succeed Dr. Mark Nelson as Chair of the Board, while Dr. Nelson will remain a Non-Executive Director. This appointment is part of the company's broader board expansion and succession planning as a dual-listed entity on the ASX and NASDAQ. Additionally, the company announced the resignation of Genevieve Ryan as Company Secretary, effective April 2, 2026. Shomalin Naidoo has been appointed as the interim Company Secretary while Telix conducts a search for a permanent replacement. Mr. Naidoo will serve as the primary contact for communications with the Australian Securities Exchange (ASX).